Page 22 - 南京医科大学学报自然科学版
P. 22

第44卷第3期
               ·312 ·                          南   京 医 科       大 学      学 报                        2024年3月


                   mor microenvironment:new mechanisms,potential thera⁃  et al. CCL1⁃CCR8 interactions:an axis mediating the re⁃
                   peutic strategies and future prospects[J]. Mol Cancer,  cruitment of T cells and Langerhans⁃type dendritic cells

                   2020,19(1):1-23                                   to sites of atopic skin inflammation[J]. J Immunol,2005,
             [9] WANG X,LANG M,ZHAO T,et al. Cancer⁃FOXP3 di⁃        174(8):5082-5091
                                               +
                   rectly activated CCL5 to recruit FOXP3 Treg cells in pan⁃  [15] HUANG Y M,MOTTA E,NANVUMA C,et al. Microglia/
                   creatic ductal adenocarcinoma[J]. Oncogene,2017,36  macrophage⁃derived human CCL18 promotes glioma pro⁃
                  (21):3048-3058                                     gression via CCR8 ⁃ ACP5 axis analyzed in humanized
             [10] JACKSON J J,KETCHAM J M,YOUNAI A,et al. Disco⁃     slice model[J]. Cell reports,2022,39(2):110670
                   very of a potent and selective CCR4 antagonist that inhib⁃  [16] BEYER M,SCHUMAK B,WEIHRAUCH M R,et al. In
                                                                                         +            +
                   its Treg trafficking into the tumor microenvironment[J]. J  vivo expansion of naïve CD4 CD25high FOXP3 regulatory
                   Med Chem,2019,62(13):6190-6213                    T cells in patients with colorectal carcinoma after IL⁃2 ad⁃
             [11] HIRATA A,HASHIMOTO H,SHIBASAKI C,et al. Intra⁃     ministration[J]. PLoS One,2012,7(1):e30422
                                                                                        +
                   tumoral IFN ⁃ α gene delivery reduces tumor ⁃ infiltrating  [17] WHITESIDE T L. FOXP3 Treg as a therapeutic target for
                   regulatory T cells through the downregulation of tumor  promoting anti ⁃ tumor immunity[J]. Expert opinion on
                   CCL17 expression[J]. Cancer Gene Ther,2019,26(9/  therapeutic targets,2018,22(4):353-363
                   10):334-343                                  [18] VAN DAMME H,DOMBRECHT B,KISS M,et al. Thera⁃
                                                                                        +
             [12] PLITAS G,KONOPACKI C,WU K M,et al. Regulatory T    peutic depletion of CCR8 tumor⁃infiltrating regulatory T
                   cells exhibit distinct features in human breast cancer[J].  cells elicits antitumor immunity and synergizes with anti⁃
                   Immunity,2016,45(5):1122-1134                     PD ⁃ 1 therapy[J]. J Immunother Cancer,2021,9(2):
             [13] TANAKA A,SAKAGUCHI S. Regulatory T cells in can⁃   e001749
                   cer immunotherapy[J]. Cell Res,2017,27(1):109-118                      [收稿日期] 2023-09-04
             [14] GOMBERT M,DIEU⁃NOSJEAN M C,WINTERBERG F,                                     (本文编辑:陈汐敏)




















                     


                                 欢迎投稿 欢迎订阅






                                                                                                         
                                                                                                         
   17   18   19   20   21   22   23   24   25   26   27